Please provide your email address to receive an email when new articles are posted on . Compared with married people, unmarried people were more likely to have a prolonged QT interval, according to ...

As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...

February 19, 2009 (Portland, Oregon) — Both diabetes and QT-interval-prolonging medications were significant and independent risk factors for sudden cardiac death (SCD) among members of a ...

The QT interval is the time from the beginning of the QRS complex (ventricular depolarization) to the end of the T wave (ventricular repolarization). The normal QT interval is controversial and ...

(HealthDay News) — Use of a computerized clinical decision support system (CDSS) may reduce the risk of prolonged QT c interval in hospitalized patients at risk for torsades de pointes, according to ...

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., July 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

ROTTERDAM, the NETHERLANDS — A new analysis of participants in a population-based cohort study suggests at least two ECGs might be useful to stratify individuals at risk for sudden cardiac death (SCD) ...

The diagnostics advisory committee considered evidence on KardiaMobile 6L for measuring QT interval from several sources, including an early value assessment report, cost and resource use report and ...

BACKGROUND: Left ventricular hypertrophy (LVH) and prolonged QT interval at ECG (QTc) are common in both obesity and arterial hypertension (AH), and are risk factors for cardiovascular disease and ...

Results to be Included in BYDUREON TM New Drug Application Resubmission in the Third Quarter of 2011 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: ...